An application of nonlinear mixed-effects modeling to pharmacokinetic data exhibiting nonlinear and time-dependent behavior

Journal of Pharmaceutical Sciences

Volumn 92, Issue 1, 2003, Pages 27-34

  Iavarone, L ^a   Gomeni, R ^a  

^a GSK   (Italy)

Author keywords

Dose dependence; Interoccasion variability; Michaelis Menten; NONMEM; Time dependence

Indexed keywords

GLYCINE RECEPTOR ANTAGONIST; GW 468816; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BAYES THEOREM; BIOASSAY; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; EXPERIMENTAL MODEL; FEMALE; MALE; MICHAELIS MENTEN KINETICS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; POPULATION RESEARCH; TOXICOKINETICS; TOXICOLOGICAL PARAMETERS;

EID: 0037225628     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10266     Document Type: Article

References (16)

1. Nestorov I. 2001. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 120(1-3):411-420.
2. Rowland M. 1980. Intra-individual variability in pharmacokinetics. In: Breimer DD, editor. Towards Better Safety of Drugs and Pharmaceutical Products. New York: Elsevier, pp 167-171.
3. Bois FY. 1999. Analysis of PBPK models for risk characterization. In: Bailer AJ, Maltoni C, Bailar JC III, Belpoggi F, Braizer JV, Soffrintti M, editors. Uncertainty in the Risk Assessment of Environment and Occupational Hazards. New York: New York Academy of Sciences, pp 317-337.
4. Bouzom F, Laveille C, Merdjan H, Jochemsen R. 2000. Use of nonlinear effect modeling for the meta-analysis of preclinical pharmacokinetic data: Application to S 20342 in the rat. J Pharm Sci 89(5):603-613.
5. Aarons L. 1993. Sparse data analysis. Eur J Drug Metab Pharmacokinet 18(1):97-100.
6. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant L, Aarons L. 1996. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30:81-93.
7. Van Bree J, Nedelman J, Steimer JL, Tse F, Robinson W, Niederberger W. 1994. Application of sparse sampling approaches in rodent toxicokinetics: A prospective view. Drug Inf J 28:63-77.
8. Burtin P, Mentre F, Van Bree J, Steimer JL. 1996. Sparse sampling for assessment of drug exposure in toxicological studies. Eur J Drug Metab Pharmacokinet 21:105-111.
9. Karlsson MO, Sheiner LB. 1993. The importance of modeling interoccasion variability in population pharmacokinetic analysis. J Pharmacokinet Biopharm 216:735-749.
10. WinNonlin™ ©1998-1999, Pharsight Corporation.
11. Beal SL, Sheiner LB. 1992. NONMEM User's Guide. San Francisco, CA: University of California.
12. Visual-NM, Graphical Interface to NONMEM, Version 2, RDPP. Montpellier, France, 1997.
13. Bozdogan H. 1987. Model selection and Akaike's information criterion (AIC): The general theory and its analytical extension. Psychometrika 52:345-370.
14. Rowland M, Tozer TN. 1995. Clinical Pharmacokinetics: Concepts and Applications. Third Edition, Chapter 11. Baltimore: Lippincott, Williams, & Wilkins.
15. Frame B, Beal SL. 1998. Non-steady state population kinetics of intravenous phenytoin. Ther Drug Monit 20(4):408-416.
16. Hing JP, Woolfrey SG, Greenslade D, Wright PM. 2001. Is mixed effect modeling or naive pooled data analysis preferred for interpretation of single sample per subject toxicokinetic data? J Pharmacokinet Pharmacodyn 28(2):193-210.